{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:28:10Z","timestamp":1788305290008,"version":"build-2803163510"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Universitair Ziekenhuis Brussel"},{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003132","name":"Agency for Innovation by Science and Technology, Flanders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003132","name":"Agentschap voor Innovatie door Wetenschap en Technologie","doi-asserted-by":"publisher","award":["110680"],"award-info":[{"award-number":["110680"]}],"id":[{"id":"10.13039\/501100003132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G.0343.13"],"award-info":[{"award-number":["G.0343.13"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Belgian Foundation Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cook Medical and Besins Healthcare"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>Does IVM of immature oocytes retrieved from small antral follicles in women with polycystic ovary syndrome (PCOS) have an impact on obstetric and neonatal outcomes compared to controlled ovarian stimulation (COS)?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>Obstetric and neonatal outcomes after IVM appear to be similar to those after COS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOW ALREADY<\/jats:title>\n                  <jats:p>Women with PCOS have an increased risk of adverse pregnancy outcomes and congenital malformations in their offspring. For patients with PCOS who require IVF, IVM of germinal vesicle (GV)-stage oocytes retrieved from antral follicles has been adopted as a mild approach ART, with improved pregnancy rates over the last two decades. Although reports of obstetrical and neonatal outcomes after IVM have been reassuring, the limited sample sizes in previous studies preclude firm conclusions, and further study is warranted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>This is a retrospective observational study analysing obstetric and neonatal data from 1036 clinical pregnancies in unique patients with PCOS who conceived following a cycle of IVM or COS between January 2010 and December 2016 in a tertiary reproductive centre. In total, 393 singleton pregnancies with a gestational age beyond 20\u00a0weeks were included. A phenotypic approach was used for the diagnosis of PCOS. Pregnancies following oocyte donation, standard IVF (as opposed to ICSI) or preimplantation genetic testing and pregnancies requiring testicular biopsy in the male partners were excluded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS,SETTING, METHODS<\/jats:title>\n                  <jats:p>Pregnancy outcomes were analysed in women with PCOS phenotype A, C or D, as defined by different combinations of the Rotterdam criteria. Data from 164 pregnancies beyond 20\u00a0weeks after IVM were compared with those from 229 pregnancies after COS. Pregnancies in the IVM group were obtained after minimal ovarian stimulation and IVF with ICSI of transvaginally collected GV oocytes that had reached the metaphase II stage in vitro after 28 to 40\u00a0h of culture. No hCG trigger was administered before oocyte retrieval. Outcome measures were analysed or reported in singleton pregnancies only and included adverse obstetric events and neonatal health parameters, in particular birthweight, prematurity, small-for-gestational age, large-for-gestational age, perinatal death and major\/minor malformation rates. The incidence of hypertensive disorders of pregnancy (HDP) and birthweight was analysed by multiple linear and logistic regression, adjusted for relevant treatment variables and maternal characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>The IVM and the COS groups differed significantly (P\u2009&lt;\u20090.001) for maternal circulating AMH levels and PCOS phenotype distribution, with more of the PCOS phenotype A in the IVM group. Pregnant women in the IVM group were younger than pregnant women in the COS group (P\u2009=\u20090.05). With regard to obstetric complications in singleton pregnancies, in the unadjusted analysis, mothers of infants in the IVM group more often had HDP (29\/164 (17.9%) vs 22\/229 (9.6%), P\u2009=\u20090.02) compared with mothers in the COS group. Singletons born after IVM and COS had a similar birthweight standard deviation score (SDS) (0.51\u2009\u00b1\u20090.94 after IVM vs 0.33\u2009\u00b1\u20091.05 after COS, P\u2009=\u20090.19). Preterm birth rate (32\u201336.9\u00a0weeks) and early preterm birth rate (&lt;32\u00a0weeks) were also similar in both groups. The total malformation rate was 4.1% in singletons after IVM and 2.4% in singletons after COS. Multivariate linear regression analysis accounting for relevant confounders demonstrated that parity was the only independent predictive factor (P\u2009=\u20090.04) for birthweight SDS. Multivariate logistic regression analysis showed that BMI, parity and type of ART (IVM as opposed to COS) were significantly correlated with the incidence of HDP. Only patients with the PCOS phenotype A showed a tendency towards a higher risk of HDP in those who underwent IVM compared to those who had COS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>The study is limited by its retrospective nature and loss to follow-up of a subset of children with no information regarding congenital malformations. Furthermore, the paediatricians who assessed the children after birth were not blinded for the type of ART procedure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>This study provides further evidence that, compared to COS, IVM of oocytes derived from small antral follicles does not adversely affect the neonatal health of the offspring of patients with PCOS. The observed increased risk of HDP in patients with PCOS phenotype A following IVM treatment warrants further scrutiny.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>Translational IVM research at Universitair Ziekenhuis Brussel (UZ Brussel) and Vrije Universiteit Brussel (VUB) has been supported by grants from the Institute for the Promotion of Innovation by Science and Technology in Flanders (Agentschap voor Innovatie door Wetenschap en Technologie\u2014IWT, project 110680), the Fund for Research Flanders (Fonds Wetenschappelijk Onderzoek\u2013Vlaanderen\u2014FWO, project G.0343.13) and the Belgian Foundation Against Cancer (HOPE project, Dossier C69). Clinical IVM research was supported by research grants from Cook Medical and Besins Healthcare. M.D.V. reports honoraria for lectures from Cook Medical and Besins Healthcare outside the submitted work. S.S.R. reports honoraria for lectures by MSD and Besins and research grants by MSD, Ferring and Merck Serono outside of the submitted work. C.B. reports personal fees from Merck-Serono, Ferring, IBSA, Finox, MSD and Abbott outside the submitted work. H.T. reports grants from Merck, MSD, Goodlife, Cook, Roche, Besins, Ferring, Mithra (now Allergan) and the Research Fund of Flanders (FWO) and consultancy fees from Finox, Abbott, Obseva and Ovascience outside the submitted work. The other authors have nothing to disclose.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/dez086","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T15:13:40Z","timestamp":1557760420000},"page":"1595-1607","source":"Crossref","is-referenced-by-count":55,"title":["Obstetric and neonatal outcome of ART in patients with polycystic ovary syndrome: IVM of oocytes versus controlled ovarian stimulation"],"prefix":"10.1093","volume":"34","author":[{"given":"L","family":"Mostinckx","sequence":"first","affiliation":[{"name":"Centre for Reproductive MedicineUZ Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Segers","sequence":"additional","affiliation":[{"name":"Centre for Medical Genetics, UZ Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Belva","sequence":"additional","affiliation":[{"name":"Centre for Medical Genetics, UZ Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Buyl","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Medical Informatics, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Santos-Ribeiro","sequence":"additional","affiliation":[{"name":"Gynecology\/Reproductive Medicine, IVI-RMA Lisboa, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Blockeel","sequence":"additional","affiliation":[{"name":"Centre for Reproductive MedicineUZ Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Smitz","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Chemistry and Radioimmunology, UZ Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Anckaert","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Chemistry and Radioimmunology, UZ Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Tournaye","sequence":"additional","affiliation":[{"name":"Centre for Reproductive MedicineUZ Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"De Vos","sequence":"additional","affiliation":[{"name":"Centre for Reproductive MedicineUZ Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,26]]},"reference":[{"key":"2019091808553121000_ref1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/humupd\/dmg044","article-title":"Ultrasound assessment of the polycystic ovary: international consensus definitions","volume":"9","author":"Balen","year":"2003","journal-title":"Hum Reprod Update"},{"key":"2019091808553121000_ref2","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/humrep\/dew103","article-title":"Neonatal health including congenital malformation risk of 1072 children born after vitrified embryo transfer","volume":"31","author":"Belva","year":"2016","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/humrep\/17.3.671","article-title":"Neonatal data on a cohort of 2889 infants born after ICSI (1991\u20131999) and of 2995 infants born after IVF (1983\u20131999)","volume":"17","author":"Bonduelle","year":"2002","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref4","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/humrep\/deq125","article-title":"Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles","volume":"25","author":"Bosch","year":"2010","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/01.AOG.0000284627.38540.80","article-title":"Obstetric outcomes and congenital abnormalities after in vitro maturation, in vitro fertilization, and intracytoplasmic sperm injection","volume":"110","author":"Buckett","year":"2007","journal-title":"Obstet Gynecol"},{"key":"2019091808553121000_ref6","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.fertnstert.2004.11.044","article-title":"Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization\u2013embryo transfer","volume":"83","author":"Cha","year":"2005","journal-title":"Fertil Steril"},{"key":"2019091808553121000_ref7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.fertnstert.2015.07.1130","article-title":"Risk of preterm birth after blastocyst embryo transfer: a large population study using contemporary registry data from Australia and New Zealand","volume":"104","author":"Chambers","year":"2015","journal-title":"Fertil Steril"},{"key":"2019091808553121000_ref8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/humrep\/15.1.165","article-title":"Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome","volume":"15","author":"Chian","year":"2000","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/humupd\/dmu001","article-title":"Neonatal outcomes among singleton births after blastocyst versus cleavage stage embryo transfer: a systematic review and meta-analysis","volume":"20","author":"Dar","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2019091808553121000_ref10","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/humrep\/dey242","article-title":"ART in Europe, 2014: results generated from European registries by ESHRE","volume":"33","author":"De Geyter","year":"2018","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/humrep\/deu286","article-title":"The type of culture medium and the duration of in vitro culture do not influence birthweight of ART singletons","volume":"30","author":"De Vos","year":"2015","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref12","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.fertnstert.2011.07.1108","article-title":"Clinical outcome of non-hCG-primed oocyte in vitro maturation treatment in patients with polycystic ovaries and polycystic ovary syndrome","volume":"96","author":"De Vos","year":"2011","journal-title":"Fertil Steril"},{"key":"2019091808553121000_ref13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/23809000.2016.1161491","article-title":"Fertility preservation in women with cancer: in vitro maturation of oocytes","volume":"1","author":"De Vos","year":"2016","journal-title":"Expert Review of Quality of Life in Cancer Care"},{"key":"2019091808553121000_ref14","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/humrep\/dew219","article-title":"Cumulative live birth rates after fresh and vitrified cleavage-stage versus blastocyst-stage embryo transfer in the first treatment cycle","volume":"31","author":"De Vos","year":"2016","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref15","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1093\/humrep\/dew208","article-title":"The definition of IVM is clear \u2013 variations need defining","volume":"31","author":"De Vos","year":"2016","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.rbmo.2018.05.003","article-title":"Cumulative live birth rates after IVF in patients with polycystic ovaries: phenotype matters","volume":"37","author":"De Vos","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"2019091808553121000_ref17","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/humrep\/der251","article-title":"An OHSS-free clinic by segmentation of IVF treatment","volume":"26","author":"Devroey","year":"2011","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref19","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.fertnstert.2018.05.019","article-title":"Let\u2019s rescue oocytes: in vitro maturation 2.0 is coming","volume":"110","author":"Escrich","year":"2018","journal-title":"Fertil Steril"},{"key":"2019091808553121000_ref20","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1093\/humrep\/des359","article-title":"Comparison of the obstetric and perinatal outcomes of children conceived from in vitro or in vivo matured oocytes in in vitro maturation treatments with births from conventional ICSI cycles","volume":"27","author":"Fadini","year":"2012","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref21","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/humrep\/dex239","article-title":"Use of the serum anti-M\u00fcllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome","volume":"32","author":"Fraissinet","year":"2017","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref22","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s10815-018-1317-z","article-title":"In vitro maturation (IVM) of oocytes in patients with resistant ovary syndrome and in patients with repeated deficient oocyte maturation","volume":"35","author":"Galv\u00e3o","year":"2018","journal-title":"J Assist Reprod Genet"},{"key":"2019091808553121000_ref23","doi-asserted-by":"crossref","first-page":"378.e1","DOI":"10.1016\/j.ajog.2015.12.040","article-title":"Neonatal and maternal outcome after blastocyst transfer: a population-based registry study","volume":"214","author":"Ginstr\u00f6m Ernstad","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"2019091808553121000_ref24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149615","article-title":"Prediction of ovarian hyperstimulation syndrome in patients treated with corifollitropin alfa or rFSH in a GnRH antagonist protocol","volume":"11","author":"Griesinger","year":"2016","journal-title":"PLoS ONE"},{"key":"2019091808553121000_ref25","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/humrep\/det034","article-title":"A prediction model to select PCOS patients suitable for IVM treatment based on anti-Mullerian hormone and antral follicle count","volume":"28","author":"Guzman","year":"2013","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13048-018-0445-5","article-title":"Live birth rate after human chorionic gonadotropin priming in vitro maturation in women with polycystic ovary syndrome","volume":"11","author":"Ho","year":"2018","journal-title":"J Ovarian Res"},{"key":"2019091808553121000_ref27","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1093\/humrep\/det249","article-title":"GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients","volume":"28","author":"Humaidan","year":"2013","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref28","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/humrep\/den085","article-title":"Gene expression profiling of human oocytes following in vivo or in vitro maturation","volume":"23","author":"Jones","year":"2008","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref29","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/humrep\/deu155","article-title":"Human in vitro oocyte maturation is not associated with increased imprinting error rates at LIT1, SNRPN, PEG3 and GTL2","volume":"29","author":"Kuhtz","year":"2014","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref30","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1093\/humrep\/dex316","article-title":"Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study","volume":"32","author":"Labarta","year":"2017","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","article-title":"Criteria, prevalence, and phenotypes of polycystic ovary syndrome","volume":"106","author":"Lizneva","year":"2016","journal-title":"Fertil Steril"},{"key":"2019091808553121000_ref32","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/humrep\/dew099","article-title":"Endometrial preparation: effect of estrogen dose and administration route on reproductive outcomes in oocyte donation cycles with fresh embryo transfer","volume":"31","author":"Madero","year":"2016","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref33","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.fertnstert.2013.08.044","article-title":"Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of blastocyst-stage versus cleavage-stage embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis","volume":"100","author":"Maheshwari","year":"2013","journal-title":"Fertil Steril"},{"key":"2019091808553121000_ref34","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/humrep\/des410","article-title":"Does long in vitro culture promote large for gestational age babies?","volume":"28","author":"M\u00e4kinen","year":"2013","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10815-014-0404-z","article-title":"A comparison of pregnancy outcomes between day 3 and day 5\/6 embryo transfers: does day of embryo transfer really make a difference?","volume":"32","author":"Maxwell","year":"2015","journal-title":"J Assist Reprod Genet"},{"key":"2019091808553121000_ref36","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1472-6483(10)61666-5","article-title":"Strategies in human in-vitro maturation and their clinical outcome","volume":"10","author":"Mikkelsen","year":"2005","journal-title":"Reprod Biomed Online"},{"key":"2019091808553121000_ref37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/humupd\/dmp008","article-title":"Metabolic features of the reproductive phenotypes of polycystic ovary syndrome","volume":"15","author":"Moran","year":"2009","journal-title":"Hum Reprod Update"},{"key":"2019091808553121000_ref38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/1471-0528.12558","article-title":"Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia","volume":"121","author":"Naver","year":"2014","journal-title":"BJOG"},{"key":"2019091808553121000_ref39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2431-8-8","article-title":"Continuous growth reference from the 24th week of gestation to 24 months by gender","volume":"8","author":"Niklasson","year":"2008","journal-title":"BMC Pediatr"},{"key":"2019091808553121000_ref40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3109\/09513590.2015.1006615","article-title":"Obstetric and perinatal outcome from single cleavage transfer and single blastocyst transfer: a matched case-control study","volume":"31","author":"Oron","year":"2015","journal-title":"Gynecol Endocrinol"},{"key":"2019091808553121000_ref41","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/humupd\/dmv029","article-title":"Pregnancy complications in women with polycystic ovary syndrome","volume":"21","author":"Palomba","year":"2015","journal-title":"Hum Reprod Update"},{"key":"2019091808553121000_ref42","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.fertnstert.2014.12.096","article-title":"In vitro maturation of oocytes is not associated with altered deoxyribonucleic acid methylation patterns in children from in vitro fertilization or intracytoplasmic sperm injection","volume":"103","author":"Pliushch","year":"2015","journal-title":"Fertil Steril"},{"key":"2019091808553121000_ref43","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.rbmo.2016.01.010","article-title":"Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes: the predictive value of anti-M\u00fcllerian hormone","volume":"32","author":"Ramezanali","year":"2016","journal-title":"Reprod Biomed Online"},{"key":"2019091808553121000_ref44","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/humrep\/dex068","article-title":"Two-year development of children conceived by IVM: a prospective controlled single-blinded study","volume":"32","author":"Roesner","year":"2017","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/humupd\/dmy033","article-title":"Fresh versus elective frozen embryo transfer in IVF\/ICSI cycles: a systematic review and meta-analysis of reproductive outcomes","volume":"25","author":"Roque","year":"2019","journal-title":"Hum Reprod Update"},{"key":"2019091808553121000_ref46","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1093\/humrep\/dex262","article-title":"An improved IVM method for cumulus-oocyte complexes from small follicles in polycystic ovary syndrome patients enhances oocyte competence and embryo yield","volume":"32","author":"Sanchez","year":"2017","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/OGX.0000000000000150","article-title":"In vitro maturation and its role in clinical assisted reproductive technology","volume":"70","author":"Sauerbrun-Cutler","year":"2015","journal-title":"Obstet Gynecol Surv"},{"key":"2019091808553121000_ref48","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.earlhumdev.2006.01.012","article-title":"Growth and development of children conceived by in-vitro maturation of human oocytes","volume":"82","author":"Shu-Chi","year":"2006","journal-title":"Early Hum Dev"},{"key":"2019091808553121000_ref49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/humrep\/15.suppl_5.68","article-title":"In-utero overgrowth in ruminants following embryo culture: lessons from mice and a warning to men","volume":"5","author":"Sinclair","year":"2000","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref50","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/humrep\/deh768","article-title":"Favourable pregnancy results with insemination of in vitro matured oocytes from unstimulated patients","volume":"20","author":"S\u00f6derstr\u00f6m-Anttila","year":"2005","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref51","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/humrep\/dei503","article-title":"Obstetric and perinatal outcome and preliminary results of development of children born after in vitro maturation of oocytes","volume":"21","author":"S\u00f6derstr\u00f6m-Anttila","year":"2006","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref52","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.fertnstert.2006.11.027","article-title":"Pregnancies and deliveries after transfer of human blastocysts derived from in vitro matured oocytes in in vitro maturation cycles","volume":"87","author":"Son","year":"2007","journal-title":"Fertil Steril"},{"key":"2019091808553121000_ref53","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00404-017-4561-z","article-title":"Predictive factors for live birth after in vitro maturation of oocytes in women with polycystic ovary syndrome","volume":"297","author":"Tannus","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"2019091808553121000_ref54","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0015-0282(16)56891-5","article-title":"In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients","volume":"62","author":"Trounson","year":"1994","journal-title":"Fertil Steril"},{"key":"2019091808553121000_ref55","article-title":"Pregnancy and neonatal complications in women with PCOS in relation to second trimester anti-M\u00fcllerian hormone levels","author":"Valdimarsdottir"},{"key":"2019091808553121000_ref56","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.fertnstert.2004.10.054","article-title":"Blastocyst formation in in vitro fertilization versus intracytoplasmic sperm injection cycles: influence of the fertilization procedure","volume":"83","author":"Van Landuyt","year":"2005","journal-title":"Fertil Steril"},{"key":"2019091808553121000_ref57","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/humrep\/deq374","article-title":"Outcome of closed blastocyst vitrification in relation to blastocyst quality: evaluation of 759 warming cycles in a single-embryo transfer policy","volume":"26","author":"Van Landuyt","year":"2011","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref58","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.rbmo.2012.08.001","article-title":"IVF versus ICSI for the fertilization of in-vitro matured human oocytes","volume":"25","author":"Walls","year":"2012","journal-title":"Reprod Biomed Online"},{"key":"2019091808553121000_ref59","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/humrep\/deu248","article-title":"In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes","volume":"30","author":"Walls","year":"2015","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref60","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/humrep\/dev125","article-title":"In vitro maturation is associated with increased early embryo arrest without impairing morphokinetic development of useable embryos progressing to blastocysts","volume":"30","author":"Walls","year":"2015","journal-title":"Hum Reprod"},{"key":"2019091808553121000_ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2018.10.006","article-title":"Effect of in vitro culture period on birth weight after vitrified-warmed transfer cycles: analysis of 4,201 singleton newborns","author":"Zhang","year":"2018","journal-title":"Fertil Steril"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/advance-article-pdf\/doi\/10.1093\/humrep\/dez086\/29002955\/dez086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/34\/8\/1595\/30034652\/dez086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T08:59:20Z","timestamp":1568797160000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/34\/8\/1595\/5538948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,26]]},"references-count":60,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,7,26]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/dez086","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,7,26]]}}}